Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Idaho-based pet medication supplier PetIQ believes the companion animal market in the US is set for healthy growth, despite the cost of medicine to owners proving to be a constant obstacle. Animal Pharm editor Joseph Harvey examined this dynamic and spoke to pricing specialist Graham Tatham of consultancy Simon-Kucher & Partners' animal health practice for his point-of-view.
Kindred Biosciences is looking at various commercial options as it aims for approval of its first product in Europe this year.
Northern Irish company Norbrook Laboratories has recalled several lots of its injectable products in the US as a precautionary measure.
The Japanese Ministry of Agriculture, Forestry and Fisheries (JMAFF) has approved an additional route of administration for DS Pharma Animal Health's Victas Injectable Solution 5% (orbifloxacin).
The US FDA has recently handed out generic approvals to three companies for both livestock and pet products.
US firm ImmuCell has reached a key milestone in the development of its Re-Tain mastitis treatment.
Ceva Santé Animale has received a positive opinion ruling from European authorities for its Forceris antiprotozoal.
The threat of antimicrobial resistance "shows no signs of slowing down", according to a report from leading European authorities.
North Carolina's Agile Sciences has begun working with Stonehaven Incubate on introducing its pipeline to the animal health space.
UK start-up PetMedix will begin drug discovery activities after securing £8 million ($10.4 million) in a series A funding round.
German start-up GeneQuine Biotherapeutics has begun R&D activities at a new laboratory in Berlin.
Zoetis now has 12 blockbuster products in its portfolio and believes another one is on the way.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.